{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"Maximum grade of physician assessed adverse events reported during treatment","groups":[{"description":"IV pulse actinomycin-D (1.25mg/m2 ) every 14 days. (2mg max dose)","id":"OG000","title":"Regimen I (Dactinomycin)"},{"description":"institutional preference of either:\n\n* IV methotrexate (0.4 mg/kg) daily for 5 days every 14 days. (25mg max daily dose) OR\n* IM methotrexate (50mg) on Days 1, 3, 5, 7 (4 doses per cycle) with Leucovorin (15mg) on Days 2, 4, 6, 8. Repeat every 14 days.","id":"OG001","title":"Regimen II (Methotrexate)"}],"paramType":"NUMBER","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"Assessed throughout the treatment period and within 2-4 weeks after discontinuation of treatment","title":"Number of Participants With CTCAE v4 Graded Adverse Events With Low-risk Gestational Trophoblastic Neoplasia by Arm","type":"SECONDARY","unitOfMeasure":"participants"}